Show simple item record

dc.contributor.authorFalla, Abby May
dc.contributor.authorHofstraat, Sanne Henrietta Ina
dc.contributor.authorDuffell, Erika
dc.contributor.authorHahné, Susan Josien Maria
dc.contributor.authorTavoschi, Lara
dc.contributor.authorVeldhuijzen, Irene Karen
dc.date.accessioned2018-02-22T12:12:46Z
dc.date.available2018-02-22T12:12:46Z
dc.date.issued2018
dc.identifier.citationHepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. 2018, 18 (1):79 BMC Infect. Dis.en
dc.identifier.issn1471-2334
dc.identifier.pmid29433454
dc.identifier.doi10.1186/s12879-018-2988-x
dc.identifier.urihttp://hdl.handle.net/10029/621433
dc.description.abstractIn 2016, the World Health Organisation set a goal to eliminate viral hepatitis by 2030. Robust epidemiological information underpins all efforts to achieve elimination and this systematic review provides estimates of HBsAg and anti-HCV prevalence in the European Union/European Economic Area (EU/EEA) among three at-risk populations: people in prison, men who have sex with men (MSM), and people who inject drugs (PWID).
dc.language.isoenen
dc.rightsArchived with thanks to BMC infectious diseasesen
dc.titleHepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.en
dc.typeArticleen
dc.identifier.journalBMC Infect Dis 2018; 18(1):79en
html.description.abstractIn 2016, the World Health Organisation set a goal to eliminate viral hepatitis by 2030. Robust epidemiological information underpins all efforts to achieve elimination and this systematic review provides estimates of HBsAg and anti-HCV prevalence in the European Union/European Economic Area (EU/EEA) among three at-risk populations: people in prison, men who have sex with men (MSM), and people who inject drugs (PWID).


This item appears in the following Collection(s)

Show simple item record